###### Strengths and limitations of this study

-   Coronary risk scores, which utilise data on multiple risk factors, are ideal for making rational decisions regarding the distribution of scarce health service resources. The Framingham risk score overestimates the coronary risk in other populations, such as contemporary populations in Europe.

-   There are no data on whether the Framingham risk score overestimates the coronary risk in Korea.

-   Fatal and non-fatal (hospitalised) events among the study cohort were identified from insurance claims which were reported to the National Health Insurance System between the date of examination and 31 December 2011, giving a median follow-up of 11.6 years.

-   This is an unusually large study with over 200 000 participants.

-   The limitations of this study include possible measurement errors and the non-random sample used.

Introduction {#s1}
============

In 2008, cardiovascular disease (CVD) accounted for 30% of total global deaths, while 80% of CVD deaths occurred in low-income and middle-income countries. Of these deaths, an estimated 7.3 million were due to coronary heart disease (CHD) and 6.2 million were due to stroke.[@R1] In Korea, CVD is now one of the leading preventable causes of death in Korea, causing 22% of all deaths in 2011.[@R2]

CHD risk scores, which utilise data on multiple risk factors, are ideal for making rational decisions regarding the distribution of scarce health service resources. The Framingham CHD Risk Score (FRS), developed in a middle-class population in Massachusetts, is the most commonly used CHD risk score worldwide. However, in recent years, several investigators have demonstrated that the FRS overestimates the coronary risk in other populations, such as contemporary populations in Europe[@R3]^--^[@R5] and Asia,[@R6] including Korea,[@R7] while others have suggested that additional risk factors may add to the predictability of those included in the FRS.[@R8]^--^[@R10] Although some studies have investigated this issue in Asian populations,[@R8] [@R9] none had a follow-up of over 10 years.

To date, no national CHD risk score has been developed for Korea, despite the existence of some very large cohort studies with the potential to produce more reliable estimates of risk associations than have previously been possible.

The objectives of this study were, thus, to evaluate the applicability of the Framingham risk function[@R11] in the Korean Heart Study (KHS) population, and to develop a Korean CHD risk score.

Method {#s2}
======

Study population {#s2a}
----------------

KHS included 430 920 individuals (266 782 men and 164 138 women) who had voluntarily undergone private health examinations in 18 centres located in the capital and six provinces in South Korea between 1996 and 2004. A full description of KHS has been previously published.[@R12] [@R13]

To develop a 10-year CHD risk prediction model, the baseline period used for this study was between 1996 and 2001; however, since we have followed them until December 2011 this gives at least 10 years of potential follow-up for everyone included ([figure 1](#BMJOPEN2014005025F1){ref-type="fig"}). Sixteen thousand five hundred and seventy-eight participants who reported of having cancer, liver disease, CVD or a respiratory disease at, or prior to, the initial visit were excluded. Also, 5408 participants with missing information on blood pressure, total serum cholesterol, fasting serum glucose, smoking status or body mass index (BMI), or who had an extremely low BMI (\<16 kg/m^2^) or height (≤1.30 m) were excluded. The final study participants were 268 315 individuals.

![Defining the study population.](bmjopen2014005025f01){#BMJOPEN2014005025F1}

Data collection {#s2b}
---------------

Data files were collected from centres that maintained electronic databases, and manual data coding was performed by trained personnel for data collected from centres that kept paper records. Smoking habits (current, former or never smoking) was ascertained from the questionnaires. Either registered nurses or blood pressure technicians measured blood pressure using a standard mercury sphygmomanometer. For clinical chemistry assays, serum was separated from peripheral venous blood samples that were obtained from each participant after 12 h of fasting and was stored at −70°C. Biomarkers, such as fasting glucose and lipid profiles, were measured using the Histachi-7600 analyser (Hitachi Ltd, Tokyo, Japan). Details on quality control were published previously.[@R12]

In 2006, the Korean Association of Quality Assurance for Clinical Pathology conducted a nationwide study of interlaboratory agreement, and the Department of Clinical Pathology at the Asan Medical Center was in charge of the analysis. After receiving written permission, we reviewed interlaboratory correlations for the participating centres. The interlaboratory correlation coefficients for all measured variables exceeded 0.95.[@R12]

Outcome variables {#s2c}
-----------------

Fatal and non-fatal (hospitalised) events among the study cohort were identified from insurance claims which were reported to the National Health Insurance System (NHIS) between the date of examination and 31 December 2011, giving a median follow-up of 11.6 years. Since NHIS is a national organisation covering all of Korea\'s population, this should provide a complete event ascertainment.

'Hard' CHD events, comprising acute myocardial infarction, sudden death and other coronary deaths, were included in our study outcome variable.[@R11] We ascertained non-fatal CHD events, defined according to the International Classification of Diseases 10th Revision (acute myocardial infarction, code I21), from health insurance claims data from the NHIS. For fatal CHD events, deaths from death records were collected. Death certificates from the National Statistical Office were identified via identification numbers, which are assigned to citizens at birth.

A validation study was conducted by 20 internists from the Korean Society of Cardiology in 2009.[@R14] For the participants who provided written permission for the use of their personal information, 673 CHD events between 1994 and 2007 were confirmed with individual hospital medical records, showing that 73% of designated myocardial infarctions were valid. The validation study was updated in 2013 with a value of 93%.[@R15] The validation study on mortality data has not been conducted.

Statistical analysis {#s2d}
--------------------

To develop the risk score, an a priori decision was made to emulate the most commonly used version of the FRS[@R11] as far as possible. Thus, age, blood pressure, total and high-density lipoprotein-cholesterol (HDL-C), diabetes and smoking were considered for inclusion in the Korean CHD risk score (KRS). Furthermore, blood pressure, total and HDL-C were analysed in the same ordinal groups as in FRS, except that blood pressure was grouped according to the most recent (7th) guidelines of the Joint National Committee on Hypertension.[@R16] Contemporary guidelines[@R17] were used to define diabetes as self-reported or fasting glucose\>=126 mg/dL. In addition, triglycerides and low-density lipoprotein (LDL)-cholesterol were considered for inclusion in the Korean risk score, in place of HDL-C, as was an extension of the definition of smoking status to include former smoking. Another a priori decision was to develop separate risk models for men and women, where, unlike the FRS, the same variables were to be used for each sex. This is thought to be the most sensible for practical applications.

To decide on what factors should enter the risk score, Cox proportional hazards regression models were fitted first to a basic set of classical risk factors: age, blood pressure, total cholesterol (TC), smoking and diabetes. Further models added, one-at-a-time, were HDL-C, LDL-cholesterol and triglycerides to this basic set. The final model was prespecified to be that with the best discrimination and risk classification of the four, averaged across the sexes. Discrimination was assessed by the c-statistic for survival data[@R18] [@R19] and other models were compared, for risk classification, with the basic model using the continuous form of the net reclassification index (NRI) for 10-year risk of CHD.

From the final model, the KRS was derived using standard methods.[@R19] Its calibration was tested by dividing participants, within each sex, into tenths of predicted risk and using the Hosmer-Lemeshow, calibration and reclassification were carried out after splitting the data randomly into 50% development and 50% validation samples.[@R20]

Comparison with the Framingham score {#s2e}
------------------------------------

We compared the regression coefficients from a Cox proportional hazard model, fitted to the KHS, with the same variables as in the FRS and the regression coefficients in the published account of the FRS[@R11] using Wald tests. We recalibrated Framingham to the KHS population[@R19] and compared this to the KRS. All analyses were conducted using SAS, V.9.1.2 (SAS Institute Inc, Cary, North California, USA).

Results {#s3}
=======

Baseline risk factors and CHD incidence rates {#s3a}
---------------------------------------------

After excluding participants with missing values for any of the FRS risk factors, 268 315 individuals (164 005 men and 104 310 women) were included in these analyses ([table 1](#BMJOPEN2014005025TB1){ref-type="table"}). These were largely middle aged at enrolment (mean age 45.8 years in men and 47.6 years in women). Those excluded due to missing values did not differ from those included, by age and sex. The mean levels of BMI and LDL-cholesterol were similar in both sexes. However, smoking was prevalent in men but uncommon in women. Similar prevalence rates for high TC and LDL-cholesterol were observed in men and women. The prevalence of reduced HDL-C and diabetes was higher in men than in women ([table 2](#BMJOPEN2014005025TB2){ref-type="table"}).

###### 

Baseline characteristic of study participants, 1996--2001, the Korean Heart Study

                                    Men          Women
  --------------------------------- ------------ ------------
  N                                 164 005      104 310
                                    Mean±SD      Mean±SD
  Age, years                        45.8±9.4     47.6±10.0
  Body mass index, kg/m^2^          23.8±2.8     23.2± 3.1
  Systolic blood pressure, mm Hg    123.3±16.7   121.0±19.6
  Diastolic blood pressure, mm Hg   78.3±11.6    75.3±11.8
  Total cholesterol, mg/dL          194.5±34.8   195.1±37.4
  HDL-cholesterol, mg/dL            47.9±10.6    54.5±12.7
  LDL-cholesterol, mg/dL            118.4±32.2   118.9±33.6
  Triglyceride, mg/dL               148.2±87.1   113.3±67.5
  Fasting glucose, mg/dL            97.1±24.2    93.6±20.6
                                                 
                                    **%**        **%**
                                                 
  Smoking status                                 
   Ex-smoker                        23.0         4.0
   Current smoker                   53.0         5.1
  Diabetes\*                        8.4          6.0
   Medication                       1.9          1.6
  Hypertension†                     28.6         24.7
   Medication                       4.4          5.3

\*Diabetes was defined as fasting serum glucose greater than 126 mg/dL or diabetic treatment history.

†Hypertension was defined as systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg or medication.

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

###### 

Baseline risk factors, person-years of follow-up and CHD events in men and women in the Korean Heart Study, aged 30--74 years, 1996--2011\*

                             Men (n=164 005)   Women (n=104 310)                             
  -------------------------- ----------------- ------------------- ------- ----------- ----- -------
  Total†                     1 961 999         2086                121.1   1 281 102   510   52.1
  Blood pressure                                                                             
   Normal                    683 826           468                 92.4    602 146     91    25.9
   Prehypertension           798 672           774                 116.7   415 032     167   48.5
   Stage-1 hypertension      347 579           539                 149.0   178 672     133   61.8
   Stage-2 hypertension      131 922           305                 194.8   85 253      119   94.2
  Total cholesterol, mg/dL                                                                   
   \<160                     293 873           173                 81.4    213 533     32    17.1
   160--199                  854 406           698                 99.8    533 694     145   45.7
   200--239                  619 971           810                 139.3   382 484     200   53.4
   240--279                  166 830           316                 185.2   123 315     93    64.1
   ≥280                      26 918            89                  355.8   28 076      40    118.7
  HDL-cholesterol, mg/dL                                                                     
   \<35                      157 245           292                 193.7   42 652      28    59.6
   35--44                    618 462           768                 140.5   242 097     128   63.5
   45--49                    438 772           427                 116.5   205 596     107   71.2
   50--59                    523 426           429                 99.0    390 158     144   45.0
   ≥60                       224 094           170                 80.7    400 598     103   36.6
  LDL-cholesterol, mg/dL                                                                     
   \<100                     562 674           372                 82.7    385 816     75    42.2
   100--129                  733 988           661                 106.6   463 200     158   46.2
   130--149                  353 968           447                 138.9   217 960     113   54.7
   ≥150                      311 369           606                 195.2   214 126     164   66.5
  TG, mg/dL                                                                                  
   \<100                     621 804           441                 87.5    685 429     134   35.9
   100--149                  583 391           609                 115.7   332 866     142   47.6
   150--199                  357 517           464                 149.0   143 896     110   65.7
   200--249                  189 163           269                 148.5   62 412      70    99.6
   ≥250                      210 123           303                 169.0   56 499      54    83.0
  Smoking status                                                                             
   Ex-smoker                 454 230           448                 94.2    51 928      24    53.8
   Current smoker            1 038 830         1271                155.0   64 612      38    88.0
  Diabetes                   162 348           399                 217.7   75 840      98    96.1

SI conversions: to convert HDL-C and TG to mmol/L, multiply by 0.0259.

\*Participants with risk factor at baseline (1996--2001).

†Mean ages of Korean were 45.8 years in men and 47.6 years in women, respectively.

¶Incidences were standardized to the age distribution in the 2005 Korean population.

CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PY, person-years; TG, triglycerides.

During an 11.6-year median follow-up, 2596 CHD events (1903 non-fatal and 693 fatal) occurred in the cohort. The average 10-year risk for CHD was 1.03% for men and 0.40% for women. Summary statistics of person-years of follow-up and CHD events by baseline risk factor level, and overall, within sex, are shown in [table 2](#BMJOPEN2014005025TB2){ref-type="table"}.

[Tables 3](#BMJOPEN2014005025TB3){ref-type="table"} (men) and [4](#BMJOPEN2014005025TB4){ref-type="table"} (women) show the HR for each level of each prognostic factor, compared to its reference. As expected, in the 10-year predictions of CHD, all five predictors in the basic model (age, blood pressure, TC, smoking and diabetes) were statistically significant in both men and women. Models 1, 2 and 3 added HDL-C, LDL-cholesterol and triglycerides, respectively, to the basic model. Among these models, model 1 was the best discriminating model (area under the curve (AUC)=0.764) for men and also the model with best reclassification of risk (NRI=0.284) compared with the basic model (to which it was superior). For women, model 3 was the best model on both criteria (AUC=0.815 and NRI=0.207). The second best model that reflects the women is model 1 (AUC=0.812 and NRI=0.177). The KRS was adopted from model 1 for both the sexes. The KRS algorithm is given in online supplementary appendix A.

###### 

HRs for CHD risk factors in men in the Korean Heart Study, aged 30--74, 1996--2011

                             Basic model              Model 1                  Model 2                  Model 3
  -------------------------- ------------------------ ------------------------ ------------------------ ------------------------
  Age                        1.13 (1.09 to 1.18)      1.13 (1.08 to 1.18)      1.13 (1.08 to 1.18)      1.13 (1.08 to 1.18)
  Blood pressure                                                                                        
   Normal                    1.00                     1.00                     1.00                     1.00
   Prehypertension           1.30 (1.16 to 1.46)      1.29 (1.15 to 1.45)      1.32 (1.17 to 1.48)      1.28 (1.14 to 1.43)
   Stage-1 hypertension      1.74 (1.53 to 1.97)      1.72 (1.52 to 1.96)      1.78 (1.57 to 2.02)      1.68 (1.48 to 1.91)
   Stage-2 hypertension      2.22 (1.91 to 2.57)      2.20 (1.90 to 2.56)      2.28 (1.97 to 2.65)      2.13 (1.84 to 2.48)
  Total cholesterol, mg/dL                                                                              
   \<160                     1.00                     1.00                     1.00                     1.00
   160--199                  1.26 (1.07 to 1.49)      1.34 (1.14 to 1.59)      1.09 (0.90 to 1.32)      1.21 (1.02 to 1.43)
   200--239                  1.81 (1.53 to 2.13)      2.02 (1.71 to 2.38)      1.23 (0.99 to 1.53)      1.67 (1.42 to 1.98)
   240--279                  2.42 (2.01 to 2.92)      2.77 (2.30 to 3.34)      1.34 (1.04 to 1.73)      2.19 (1.81 to 2.65)
   ≥280                      3.79 (2.93 to 4.91)      4.45 (3.44 to 5.76)      2.02 (1.47 to 2.77)      3.37 (2.59 to 4.38)
  Smoking                                                                                               
   Never                     1.00                     1.00                     1.00                     1.00
   Former                    1.01 (0.88 to 1.16)      1.02 (0.89 to 1.17)      1.02 (0.89 to 1.17)      1.00 (0.87 to 1.15)
   Current                   1.93 (1.72 to 2.17)      1.86 (1.65 to 2.09)      1.96 (1.75 to 2.21)      1.87 (1.66 to 2.11)
  Diabetes                                                                                              
   No                        1.00                     1.00                     1.00                     1.00
   Yes                       1.69 (1.51 to 1.89)      1.63 (1.46 to 1.82)      1.72 (1.53 to 1.92)      1.65 (1.48 to 1.85)
  HDL-cholesterol, mg/dL                                                                                
   \<35                                               1.00                                              
   35--44                                             0.66 (0.57 to 0.75)                               
   45--49                                             0.56 (0.48 to 0.65)                               
   50--59                                             0.45 (0.39 to 0.52)                               
   ≥60                                                0.34 (0.28 to 0.41)                               
  LDL-cholesterol, mg/dL                                                                                
   \<100                                                                       1.00                     
   100--129                                                                    1.23 (1.06 to 1.43)      
   130--149                                                                    1.50 (1.25 to 1.80)      
   ≥150                                                                        1.97 (1.61 to 2.40)      
  Triglycerides, mg/dL                                                                                  
   \<100                                                                                                1.00
   100--149                                                                                             1.21 (1.07 to 1.37)
   150--199                                                                                             1.35 (1.18 to 1.54)
   200--249                                                                                             1.39 (1.19 to 1.63)
   ≥250                                                                                                 1.30 (1.11 to 1.52)
  ROC (95% CI)               0.756 (0.745 to 0.766)   0.764 (0.752 to 0.774)   0.758 (0.747 to 0.769)   0.757 (0.746 to 0.768)
  Continuous NRI (95% CI)    Referent model           0.284 (0.231 to 0.339)   0.185 (0.124 to 0.246)   0.109 (0.051 to 0.162)

SI conversions: to convert HDL-C and TC to mmol/L, multiply by 0.0259.

CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NRI, net reclassification index; ROC, receiver operating characteristic; TC, total cholesterol.

###### 

HRs for CHD risk factors in women in the Korean Heart Study, aged 30--74, 1996--2011

                             Basic model              Model 1                  Model 2                  Model 3
  -------------------------- ------------------------ ------------------------ ------------------------ ------------------------
  Age                        1.14 (1.03 to 1.26)      1.13 (1.02 to 1.24)      1.14 (1.03 to 1.26)      1.12 (1.01 to 1.24)
  Blood pressure                                                                                        
   Normal                    1.00                     1.00                     1.00                     1.00
   Prehypertension           1.61 (1.24 to 2.09)      1.57 (1.21 to 2.04)      1.61 (1.32 to 2.09)      1.54 (1.19 to 2.01)
   Stage-1 hypertension      2.01 (1.52 to 2.66)      1.93 (1.46 to 2.56)      2.01 (1.52 to 2.66)      1.88 (1.42 to 2.50)
   Stage-2 hypertension      3.15 (2.35 to 4.21)      3.02 (2.26 to 4.05)      3.15 (2.36 to 4.22)      2.90 (2.17 to 3.89)
  Total cholesterol, mg/dL                                                                              
   \<160                     1.00                     1.00                     1.00                     1.00
   160--199                  1.17 (0.80 to 1.72)      1.26 (0.86 to 1.86)      1.10 (0.71 to 1.69)      1.12 (0.76 to 1.65)
   200--239                  1.45 (0.99 to 2.12)      1.62 (1.10 to 2.38)      1.29 (0.79 to 2.10)      1.31 (0.87 to 2.00)
   240--279                  1.53 (1.01 to 2.31)      1.77 (1.16 to 2.68)      1.36 (0.78 to 2.38)      1.32 (0.87 to 2.00)
   ≥280                      2.38 (1.48 to 3.82)      2.78 (1.72 to 4.50)      2.12 (1.14 to 3.95)      1.96 (1.21 to 3.18)
  Smoking                                                                                               
   Never                     1.00                     1.00                     1.00                     1.00
   Former                    1.17 (0.78 to 1.77)      1.20 (0.79 to 1.80)      1.17 (0.78 to 1.77)      1.19 (0.79 to 1.80)
   Current                   2.06 (1.47 to 2.87)      2.00 (1.43 to 2.79)      2.06 (1.48 to 2.88)      1.95 (1.39 to 2.72)
  Diabetes                                                                                              
   No                        1.00                     1.00                     1.00                     1.00
   Yes                       1.96 (1.57 to 2.45)      1.89 (1.51 to 2.37)      1.96 (1.57 to 2.46)      1.84 (1.47 to 2.30)
  HDL-cholesterol, mg/dL                                                                                
   \<35                                               1.00                                              
   35--44                                             0.79 (0.52 to 1.19)                               
   45--49                                             0.86 (0.56 to 1.31)                               
   50--59                                             0.66 (0.44 to 1.00)                               
   ≥60                                                0.51 (0.33 to 0.78)                               
  LDL-cholesterol, mg/dL                                                                                
   \<100                                                                       1.00                     
   100--129                                                                    1.11 (0.80 to 1.54)      
   130--149                                                                    1.16 (0.79 to 1.72)      
   ≥150                                                                        1.13 (0.74 to 1.74)      
  Triglyceride, mg/dL                                                                                   
   \<100                                                                                                1.00
   100--149                                                                                             1.19 (0.93 to 1.51)
   150--199                                                                                             1.61 (1.23 to 2.09)
   200--249                                                                                             2.13 (1.58 to 2.89)
   ≥250                                                                                                 1.63 (1.17 to 2.27)
  ROC (95% CI)               0.809 (0.789 to 0.829)   0.812 (0.792 to 0.833)   0.809 (0.789 to 0.829)   0.815 (0.795 to 0.835)
  Continuous NRI (95% CI)    Referent model           0.177 (0.043 to 0.313)   0.160 (0.019 to 0.295)   0.207 (0.087 to 0.336)

SI conversions: to convert HDL-C and TC to mmol/L, multiply by 0.0259.

CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NRI, net reclassification index; ROC, receiver operating characteristic; TC, total cholesterol.

Comparison of the Framingham and the Korean risk equations {#s3b}
----------------------------------------------------------

Compared with the HRs from the KHS using the same variables, there were no big differences with the published HRs for Framingham, with the exception of LDL-cholesterol ([table 5](#BMJOPEN2014005025TB5){ref-type="table"}). The FRS overestimated, overall by a factor of six, the number of CHD events actually observed in the KHS. [Figure 2](#BMJOPEN2014005025F2){ref-type="fig"} shows the agreement between the original and recalibrated Framingham function and the KRS in the KHS population. The KRS and recalibrated FRS are clearly in close agreement, as would be anticipated from [table 5](#BMJOPEN2014005025TB5){ref-type="table"}.

###### 

HRs of coronary events in Framingham and Korean studies in men and women

                            Men                 Women                                                                
  ------------------------- ------------------- ------------------- -------- ------------------- ------------------- ----------
  Age (year)                1.05 (1.04--1.06)   1.07 (1.06--1.07)   0.0040   1.04 (1.03--1.06)   1,09 (1.08--1.11)   \<0.0001
  Blood pressure (mm Hg)                                                                                             
   Optimal+normal           1.00                1.00                         1.00                1.00                
   High normal              1.32 (0.98--1.78)   1.28 (1.13--1.45)   0.8352   1.34 (0.88--2.05)   1.40 (1.07--1.83)   0.8659
   Stage 1                  1.73 (1.32--2.26)   1.62 (1.46--1.81)   0.6668   1.75 (1.21--2.54)   1.65 (1.31--2.09)   0.7907
   Stage 2--4               1.92 (1.36--2.24)   2.10 (1.83--2.40)   0.6409   2.19 (1.46--3.27)   2.61 (2.04--3.34)   0.4701
  LDL-cholesterol (mg/dL)                                                                                            
   \<130                    1.00                1.00                         1.00                1.00                
   130--159                 1.19 (0.91--1.54)   1.56 (1.42--1.73)   0.0611   1.24 (0.84--1.81)   1.24 (1.01--1.53)   0.9931
   ≥160                     1.74 (1.36--2.34)   2.34 (2.09--2.62)   0.0326   1.68 (1.17--2.40)   1.43 (1.14--1.79)   0.4602
  HDL-cholesterol (mg/dL)                                                                                            
   \<35                     1.46 (1.15--1.85)   1.68 (1.48--1.90)   0.3092   2.08 (1.33--3.25)   1.25 (0.85--1.84)   0.0911
   35--59                   1.00                1.00                         1.00                1.00                
   ≥60                      0.61 (0.41--0.91)   0.66 (0.57--0.78)   0.7080   0.64 (0.47--0.87)   0.72 (0.58--0.89)   0.5517
  Smoking (yes/no)          1.71 (1.39--2.10)   1.89 (1.72--2.07)   0.3917   1.49 (1.13--1.97)   1.95 (1.40--2.72)   0.2230
  Diabetes (yes/no)         1.47 (1.04--2.08)   1.71 (1.53--1.91)   0.4182   1.80 (1.18--2.74)   1.96 (1.57--2.45)   0.7276

The regression coefficients for the Framingham and Korean cohorts were compared using a two-tailed z statistic, where z=(b\[F\]−b\[C\])/SE.

The SE is the standard error of the difference in coefficients, and SE=(SE\[F\]^2^+SE\[K\]^2^)^1/2^.

*Source*: Wilson *et al*.[@R1][@R1]

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

![Agreement between both the original and recalibrated Framingham risk scores and the Korean risk score for coronary heart disease, by 10th of the predicted risks from the Korean risk score.](bmjopen2014005025f02){#BMJOPEN2014005025F2}

Discussion {#s4}
==========

The objectives of this study were (1) to develop a Korean CHD model; (2) to evaluate the ability of the FRS to predict the 10-year CHD risk in the Korean population. Over 2700 first CHD events occurred in this cohort of over 268 000 Koreans in 11.6 years. The KRS was developed based on these data. When compared with the actual CHD cases, the KRS performed well, but not substantially better than a recalibrated version of the FRS.

Estimation of absolute risk required for treatment and for prevention of CHD commonly relies on prediction models developed from the experience of prospective cohort studies.[@R8]^--^[@R10] [@R21] Although prediction algorithms developed by the Framingham investigators have been widely adopted to formulate clinical guidelines in the USA and elsewhere,[@R21] the Framingham functions have overestimated the CHD risk in some populations, leading to a concern that it may not be appropriate to other populations.[@R3]^--^[@R6] [@R8] In our study, the FRS also overestimated the risk of CHD in the Korean population, where CHD incidence is relatively low. Another factor of relevance is the inclusion of softer CHD end points in the derivation of the FRS than we used in deriving the KHS.

Several studies[@R3] [@R6] have examined CHD events in the Framingham Heart Study (FHS). Due to problems anticipated risk Framingham, Ahn *et al*[@R7] previously suggested the need for Korean guidelines for the management of CHD to avoid artificial inflation of costs in primary prevention.

To compare the CHD risk factors in men and women in the KHS to those in the FHS, the same six variables that were examined in the FHS paper were analysed---age (year), blood pressure (mm Hg), TC (mg/dL), HDL-C (mg/dL), diabetes and smoking. The FHS did not yield significant HDL-C ≥60 mg/dL results for men (RR, 0.63, 95% CI 0.34 to 1.18) and women (RR, 0.58, 95% CI 0.33 to 1.02).[@R6] [@R21] In Korean men, however, 11% had HDL-C ≥60 mg/dL (RR, 0.33, 95% CI 0.28 to 0.41), a 66% (RR, 0.34) decrease in risk compared with KHS men with HDL-C \<35 mg/dL. The considerable reduction of CHD risk in participants with higher HDL-C levels reinforces the need for Korean populations to monitor their cholesterol levels closely.

Hippisley-Cox *et al*[@R22] also developed, validated and evaluated a new QRISK model to estimate lifetime risk of CVD in the UK. This model was made in light of the emergence of a new cardiovascular risk prediction tool, which was shown to have greater predictive ability than the Framingham risk equation.[@R23] Without recalibration they urge caution in using the FRS to identify high risk patients in the UK. Recently, the key issue is the extent of reallocation. Allocation is critically dependent on the cardiovascular risk score used and its performance in contemporaneous, ethnically diverse UK populations.[@R24]

The strengths of this cohort study include a large sample size, a wide age range and a nationally representative sample. The KHS cohort consisted of 268 315 participants aged 30--74 years, which was compared to 5251 participants aged 30--74 in the FHS. Examination of alternative lipid variables, triglycerides and LDL-cholesterol, and finer classification of smoking habits to include former smokers, strengthens this study. Moreover, discrimination, calibration and reclassification are all considered here, using contemporary methods.[@R19] The limitations of this study include possible measurement errors. Clinical data from the health promotion centres were one-time measurements of blood pressure and medical examinations. Also, participants might have under-reported the smoking status and alcohol consumption in the self-report questionnaires. In addition, the validation study on mortality data has not been conducted.

In conclusion, we developed a CHD prediction model for Koreans and compared the estimates from the model with the actual CHD cases. This new model provides an accurate prediction of the risk of CHD among Korean. With the gradual rise in CHD events among Koreans, the prevention and treatment of CHD risk factors such as hypertension, hypercholesterolaemia and diabetes are important public health concerns.
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